Tacrolimus (FK506): A new immunosuppressant for steroid refractory inflammatory bowel disease (IBD)

Klaus Fellermann(Apple (Israel)), Eduard F. Stange(John Radcliffe Hospital), Nils Homann(Fraunhofer Project Centre Wolfsburg), Thomas Witthoeft(University of Lübeck), Klaus Herrlinger(Robert Bosch Hospital), D Ludwig

Gastroenterology

April 1, 2000

10.1016/s0016-5085(00)85287-7

Cited by 6

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Reduced Paneth cell α-defensins in ileal Crohn's disease

|Proceedings of the National Academy of Sciences|2005|969

NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression

|Gut|2004|798

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

|Journal of Clinical Oncology|2008|784

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

|The Lancet Oncology|2016|738